Cough, Weight Loss, and a Positive Interferon-Gamma Test
A 34-year-old man presents with a 6-week history of dry cough, night sweats, low-grade fever, and 6 kg unintentional weight loss. He works as a prison guard and recently returned from a region with high tuberculosis prevalence. Examination: temperature 37.6 °C, HR 88/min, SpO2 96% on room air, BMI 20.5 kg/m². Chest X-ray shows upper-lobe cavitation on the right. Sputum smear for acid-fast bacilli is negative on two samples; an interferon-gamma release assay is positive. HIV testing is negative. Liver enzymes are mildly elevated (ALT 62 U/L, upper limit 40).
1. How do you interpret the negative sputum smears in the context of the positive interferon-gamma release assay and cavitary disease?
Read the worked answer
Interpretation:
- The positive IGRA indicates tuberculosis infection but cannot distinguish latent from active disease; here the cavitary upper-lobe disease plus systemic symptoms strongly suggest active pulmonary tuberculosis.
- Negative smears do not exclude active TB. Smear sensitivity is limited, especially with low bacillary load; culture and molecular testing (e.g., PCR-based assays such as Xpert MTB/RIF) are more sensitive and should be sent.
- The occupational exposure (prison) and travel history raise pretest probability.
- Do not treat as latent TB; latent infection would not explain cavitation and weight loss.
- Continue to collect adequate sputum samples (including induced sputum or bronchoscopy if needed) for culture and drug-susceptibility testing.
2. Outline the initial management, including infection-control measures and the approach to his mildly elevated liver enzymes.
Read the worked answer
Management:
- Notify public health and arrange airborne isolation (negative-pressure room, N95 respirator for staff) until he is on effective therapy and deemed non-infectious per local criteria.
- Start standard multidrug anti-TB therapy (typically isoniazid, rifampicin, pyrazinamide, ethambutol) once specimens are obtained; do not wait for culture if clinical suspicion is high.
- Baseline monitoring: liver enzymes (already mildly elevated), bilirubin, renal function, visual acuity (ethambutol), and color vision.
- Mild ALT elevation (62 U/L) is not a contraindication; monitor closely, and stop hepatotoxic drugs if ALT rises substantially (e.g., >3–5× ULN with symptoms, or >5× without symptoms, per protocol), excluding other causes.
- Contact tracing of household and workplace contacts; screen prison contacts.
- Adherence support and directly observed therapy where available; consider pyridoxine with isoniazid to prevent neuropathy.
- Drug-susceptibility testing on culture to guide therapy.
3. What specific counseling would you give about drug interactions and adverse effects before he leaves?
Read the worked answer
Counsel on:
- Rifampicin induces hepatic enzymes and reduces efficacy of many drugs (oral contraceptives, warfarin, some antiretrovirals, corticosteroids, azoles); advise alternative contraception and review all medications.
- Rifampicin turns urine, sweat, and tears orange-red - harmless but expected.
- Isoniazid can cause peripheral neuropathy (mitigated by pyridoxine) and hepatitis.
- Pyrazinamide can cause hyperuricemia and hepatotoxicity.
- Ethambutol can cause optic neuritis with color-vision changes - report visual symptoms promptly.
- Alcohol avoidance to reduce hepatotoxicity.
- Adherence is critical to prevent relapse and resistance; explain the full duration (typically 6 months for drug-susceptible disease) and follow-up schedule.
- Report jaundice, dark urine, rash, or visual changes immediately.